scispace - formally typeset
N

Nan Lin

Researcher at Harvard University

Publications -  1220
Citations -  65601

Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.

Papers
More filters
Journal ArticleDOI

Research studies in patterns of scientific communication: III. Information-exchange processes associated with the production of journal articles☆

TL;DR: How scientists assimilate and use information contained in these articles when this information is also disseminated via informal media prior to its appearance in journal articles is discussed.
Journal ArticleDOI

The Left Fusiform Gyrus is a Critical Region Contributing to the Core Behavioral Profile of Semantic Dementia

TL;DR: It is found that the gray matter volumes of two regions [left fusiform gyrus (lFFG) and left parahippocampal gyrus) significantly correlated with the semantic scores of patients with SD and that the lFFG could be a critical region contributing to the semantic deficits of SD.
Journal ArticleDOI

Exposure and size distribution of nitrated and oxygenated polycyclic aromatic hydrocarbons among the population using different household fuels

TL;DR: The inhalation exposure levels for residents adopting wood gasifier burners was significantly lower than the documented results for those burning wood in typical built-in brick stoves, and comparable to those using LPG and electricity, which provided vital information for clean stove development and intervention programs.
Journal ArticleDOI

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

TL;DR: In this article , a syngeneic genetically-engineered mouse model of breast tumor driven by Brca1 deficiency was used to demonstrate the importance of targeting innate immune suppression to facilitate PARPi-mediated engagement of anti-tumor immunity in breast cancer.